Interview with Johan Ström Managing Director, Biogen Idec Sweden
Having experienced many years at big pharmaceutical companies, you moved into the biotech sector by joining Biogen Idec late 2010. What made you decide to switch? To me, it was…
Company Description
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
BiogenIdec Sweden AB
Kanalvägen 12, Plan 5
19461 Upplands Väsby
Sweden
Phone: +46 8 5941 1360
Fax: +46 8 5941 1369
www.biogenidec.se
Having experienced many years at big pharmaceutical companies, you moved into the biotech sector by joining Biogen Idec late 2010. What made you decide to switch? To me, it was…
The general manager of Baxter in the Nordic region discusses the concept of home care, and how brand new technologies currently being tested in Sweden should mean that soon, dialysis…
After working at Ipsen for seven years, of which you have spent four as the head of the Nordics, what would you say have been the company’s main milestones in…
Marku Santonen, before becoming General Manager of Amgen’s Nordic and Baltic division, worked with some of the biggest names in the industry. Most notably as Marketing Manager for Europe at…
Marku Santonen, before becoming General Manager of Amgen’s Nordic and Baltic division, worked with some of the biggest names in the industry. Most notably as Marketing Manager for Europe at…
Marku Santonen, before becoming General Manager of Amgen’s Nordic and Baltic division, worked with some of the biggest names in the industry. Most notably as Marketing Manager for Europe at…
“The Nordic region—the ‘quiet North’ as it could have been called—counterbalances the turbulence in Southern Europe,” says Zinta Krumins, managing director Nordics, Boehringer Ingelheim, when asked about the relevance of…
Could you begin by introducing Diamyd Medical and therapeutic focus to those of our international readership that are not yet familiar with your name? Diamyd was recently listed on Nasdaq’s…
Could you begin by giving a short introduction to Nordic Drugs and its current position within the structure of owner Nordic Group? Nordic Drugs started as a 100% owned subsidiary…
As the blockbuster sales model fades, the rush is on for a new formula for growth, termed ‘Good growth’ by Pharmaceutical Executive: niched, balanced & sustainable with high margins from…
You refer to AstraZeneca as the locomotive of bioscience in Sweden. Can you elaborate on what you mean by that, and the role that you see for AstraZeneca in pushing…
Having experienced many years at big pharmaceutical companies, you moved into the biotech sector by joining Biogen Idec late 2010. What made you decide to switch? To me, it was…
Last year, Boston Scientific took important steps to stabilise and strengthen its core businesses. Could you develop on the development trajectory of Boston Scientific in the Nordic region so far?…
See our Cookie Privacy Policy Here
